Loading…
Beam Therapeutics Inc. is projected to rise to $28.90 by 2027, a +9% move from its current price of $26.49. BEAM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $25.64 | $26.51 | $27.40 | +0.06% |
| Aug 2 | $25.30 | $26.52 | $27.80 | +0.12% |
| Aug 3 | $25.05 | $26.54 | $28.11 | +0.17% |
| Aug 4 | $24.84 | $26.55 | $28.38 | +0.23% |
| Aug 5 | $24.66 | $26.57 | $28.62 | +0.29% |
| Aug 6 | $24.50 | $26.58 | $28.85 | +0.35% |
| Aug 7 | $24.35 | $26.60 | $29.05 | +0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.35 | $26.60 | $29.05 | +0.41% |
| Week 2 | $23.57 | $26.71 | $30.26 | +0.82% |
| Week 3 | $23.01 | $26.81 | $31.24 | +1.23% |
| Week 4 | $22.57 | $26.92 | $32.12 | +1.64% |
| Week 5 | $22.19 | $27.03 | $32.93 | +2.05% |
| Week 6 | $21.87 | $27.14 | $33.69 | +2.47% |
| Week 7 | $21.58 | $27.25 | $34.42 | +2.89% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Beam Therapeutics Inc. is a biotechnology company that engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It was incorporated in 2017 and is based in Cambridge, Massachusetts.
Its hematology and genetic disease portfolio includes Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. Beam also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs, and BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE.
The company maintains research collaborations with Pfizer Inc., Verve Therapeutics, Inc., and Orbital Therapeutics to design and pursue therapies across liver, muscle, and central nervous system targets. These programs and partnerships form the core of Beam’s strategy in precision genetic medicines and related platforms.
Beam Therapeutics Inc. (BEAM) is currently priced at $26.33 with a market capitalization of $2.71B, and it ranks 1733 by market cap. The stock’s price outlook is captured in a year-by-year forecast that starts with a neutral stance in 2026 and shifts to a bullish trajectory through 2050.
In 2026, the forecast shows an average price of $26.33, with a range from $21.90 to $38.82, and a 0 ROI. The path remains neutral to slightly bullish into 2027, and then improves steadily, reaching an average of $43.18 by 2030 and climbing to $218.94 by 2050, with substantial upside potential reflected in higher max values and multi-year ROIs.
A major floor 35.9% below — a decisive break under it would weaken the trend.
The nearest floor, 5.4% below — buyers have tended to step in here.
The nearest ceiling, 43.1% above — a clean break opens room to run.
A major ceiling 61.1% above — clearing it would confirm fresh momentum.
Key BEAM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BEAM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $25.79 | Buy | $26.20 | Buy |
| MA 10 | $26.27 | Buy | $26.94 | Sell |
| MA 20 | $29.86 | Sell | $28.57 | Sell |
| MA 50 | $30.75 | Sell | $29.91 | Sell |
| MA 100 | $29.23 | Sell | $29.49 | Sell |
| MA 200 | $28.10 | Sell | $28.02 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.76 | Neutral |
| Stoch RSI (14) | 61.12 | Neutral |
| CCI (20) | -60.07 | Neutral |
| Williams %R (14) | -76.05 | Info |
| MACD (12,26,9) | -0.39 | Sell |
| ROC (12) | -14.24 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 23.95 | Neutral |
| TRIX (15) | -0.64 | Sell |
| Awesome (5,34) | -5.34 | Sell |
| Ultimate (7,14,28) | 34.89 | Neutral |
| Momentum (10) | -1.90 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 25.92 | Buy |
| ADX (14) | 23.55 | Sell |
| ATR (14) | 0.93 | Info |
The 30-day technical picture is neutral, with RSI14 at 30 and the sentiment labeled NEUTRAL. The near-term moving averages show SMA50 at $31.43 and SMA200 at $28.10, suggesting price pressure below the short-term average.
Support is identified at $26.33 and resistance at $37.92, placing the current price near support but within a framework of potential upside if momentum turns. The 30-day range spans from $20.41 to $33.96, highlighting notable volatility within the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $21.90 | $26.49 | $38.27 | 0% | Neutral | |
| $22.58 | $28.90 | $39.38 | +9% | Neutral | |
| $24.54 | $32.54 | $46.35 | +23% | Bullish | |
| $26.49 | $36.17 | $53.34 | +37% | Bullish | |
| $31.35 | $43.93 | $66.67 | +66% | Bullish | |
| $37.34 | $53.58 | $83.37 | +102% | Bullish | |
| $37.18 | $54.55 | $86.78 | +106% | Bullish | |
| $38.37 | $57.49 | $93.32 | +117% | Bullish | |
| $39.73 | $60.73 | $100.41 | +129% | Bullish | |
| $39.46 | $61.49 | $103.42 | +132% | Bullish | |
| $53.63 | $91.29 | $164.83 | +245% | Bullish | |
| $112.34 | $223.59 | $447.21 | +744% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $21.90 | $26.49 | $30.96 | +0.00% |
| August 2026 | $23.56 | $27.78 | $33.62 | +4.88% |
| September 2026 | $23.45 | $27.93 | $34.35 | +0.54% |
| October 2026 | $23.36 | $28.06 | $34.95 | +0.47% |
| November 2026 | $24.31 | $29.39 | $36.99 | +4.75% |
| December 2026 | $24.76 | $30.13 | $38.27 | +2.51% |
Click any year to see its month-by-month BEAM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BEAM price prediction for 2026 points to an average of $26.49 (low $21.90, high $38.27) — a potential gain of 0% on today's $26.49. Price action looks broadly range-bound.
In 2027, BEAM is projected to trade between $22.58 and $39.38, averaging $28.90 — a potential gain of +9% from today's $26.49. That is up +9% on the projected 2026 average. A consolidation phase looks the most probable path here.
Beam Therapeutics Inc.'s 2028 outlook centres on $32.54, within a $24.54 to $46.35 range. That is up +13% on the projected 2027 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2029, BEAM could reach as high as $53.34, with a base case around $36.17 and support toward $26.49 — roughly +37% from $26.49. Buyers look set to stay in control over this stretch.
Expect BEAM to range from $31.35 to $66.67 through 2030. The $43.93 average target implies a +66% move from current prices. That is up +21% on the projected 2029 average. Momentum favours further upside here.
The BEAM price prediction for 2031 points to an average of $53.58 (low $37.34, high $83.37) — a potential gain of +102% on today's $26.49. Buyers look set to stay in control over this stretch.
In 2032, BEAM is projected to trade between $37.18 and $86.78, averaging $54.55 — a potential gain of +106% from today's $26.49. That is up +2% on the projected 2031 average. Momentum favours further upside here.
Beam Therapeutics Inc.'s 2033 outlook centres on $57.49, within a $38.37 to $93.32 range. That is up +5% on the projected 2032 average. That marks a +117% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, BEAM could reach as high as $100.41, with a base case around $60.73 and support toward $39.73 — roughly +129% from $26.49. Momentum favours further upside here.
Expect BEAM to range from $39.46 to $103.42 through 2035. The $61.49 average target implies a +132% move from current prices. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The BEAM price prediction for 2040 points to an average of $91.29 (low $53.63, high $164.83) — a potential gain of +245% on today's $26.49. Momentum favours further upside here.
In 2050, BEAM is projected to trade between $112.34 and $447.21, averaging $223.59 — a potential gain of +744% from today's $26.49. That is up +145% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BEAM today (≈ 37.750094 BEAM) could be worth
$8,440.42
+$7,440.42 (+744%) by 2050 · US Dollar
Based on the average projected BEAM price of $223.59 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BEAMwould be worth at today's price.
$1,000 invested in BEAM on Jul 30, 2025 (≈ 49.627793 BEAM) would be worth
$1,314.64
+$314.64 (+31.5%) today · 1.31× · US Dollar
Based on a BEAM entry price of $20.15 vs. today's $26.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $25.91 | $1,022.39 | +2.2% |
| 1 month ago | $34.32 | $771.85 | -22.8% |
| 3 months ago | $30.7 | $862.87 | -13.7% |
| 6 months ago | $27.62 | $959.09 | -4.1% |
| 1 year ago | $20.15 | $1,314.64 | +31.5% |
| All time (5.0y) ago | $90.6 | $292.38 | -70.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BEAM forecast.
Our base-case forecast reaches $53.00 around 2031.
Implied market cap at $53.00: $5.45B
The multi-year forecast portrays a bullish trajectory after 2027, with 2028 at an average of $32.27 and 2029 at $35.21. By 2030, the average price is projected to be $43.18 with a 64 ROI, and by 2031 the average rises to $54.13 with a 105.6 ROI. The sequence continues through 2032 ($53.50, 103.2 ROI) and 2033 ($56.25, 113.7 ROI), followed by 2034 ($59.98, 127.8 ROI) and 2035 ($58.11, 120.7 ROI).
Looking further out, 2040 shows an average of $89.13 with a 238.5 ROI, and 2050 projects a strong ascent to an average of $218.94 with a 731.5 ROI and a max of $466.98. These figures indicate a sustained, substantial upside over the long term, but they are estimates and not guarantees. Investors should consider the inherent uncertainties in clinical development, regulatory outcomes, and market dynamics when interpreting this forecast.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $43.18 with a min of $29.73 and a max of $68.01, and a 64 ROI.
The forecast depicts a bullsih path beyond 2027, with the average price rising to $218.94 by 2050 and a 731.5 ROI. However, these are estimates and not guarantees, and risk factors should be considered.
Yes. The forecast max reaches $103.88 in 2034 and $102.56 in 2035, with higher max values of $170.07 in 2040 and $466.98 in 2050.
Current price: $26.33. Market cap: $2.71B.
Avg $218.94, min $98.52, max $466.98, with ROI 731.5.
Beam Therapeutics Inc. Community Discussion
0Share your Beam Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.